Diseases
Companies
Products
Productz
Mechanisms of Action
Sites
JAB-26766
/
Jacobio Pharma
Welcome,
Profile
Billing
Logout
Diseases
Trials
Trials
News
||||||||||
JAB-26766
/
Jacobio Pharma
JAB-26766: A small-molecule, orally bioavailable PARP7 inhibitor with high potency and selectivity
(Section 22) - Mar 5, 2024 - Abstract #AACR2024AACR_6872;
JAB-26766 is an orally bioavailable, highly potent, and selective PARP7 inhibitor that shows early promising anti-tumor activities.